Patents Represented by Attorney, Agent or Law Firm Law Offices of Jane Massey Licata
  • Patent number: 6303374
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of caspase 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 3. Methods of using these compounds for modulation of caspase 3 expression and for treatment of diseases associated with expression of caspase 3 are provided.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: October 16, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Hong Zhang, Lex M. Cowsert
  • Patent number: 6238921
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: May 29, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia
  • Patent number: 6235527
    Abstract: A glial precursor cell population from mammalian central nervous system has been isolated. These A2B5+ E-NCAM− glial-restricted precursor (GRP) cells are capable of differentiating into oligodendrocytes, A2B5+ process-bearing astrocytes, and A2B5− fibroblast-like astrocytes, but not into neurons. GRP cells can be maintained by regeneration in culture. GRP cells differ from oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells in growth factor requirements, morphology, and progeny. Methods of use of GRP cells are also disclosed.
    Type: Grant
    Filed: November 29, 1997
    Date of Patent: May 22, 2001
    Assignee: University of Utah Research Foundation
    Inventors: Mahendra S. Rao, Mark Noble, Margot Mayer-Proschel
  • Patent number: 6235723
    Abstract: Compositions and methods are provided for modulating the expression of PKC-&dgr; and for the treatment and diagnosis of diseases associated with protein kinase C-&dgr;. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C-&dgr; expression with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to PKC-&dgr; are disclosed. Methods of modulating the expression of TNF-a using the compositions of the present invention are also provided.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: May 22, 2001
    Assignee: Isis Pharmaceuticals , Inc.
    Inventor: Nicholas M. Dean
  • Patent number: 6221850
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: April 24, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela Scott Nero, William A. Gaarde
  • Patent number: 6214334
    Abstract: Methods of treating individuals suspected of suffering from diseases, conditions or disorders of the Central Nervous System which comprise implanting stable, homogeneous post-mitotic human neurons into the individual's brain are disclosed. Methods of treating individuals suspected of suffering from injuries, diseases, conditions or disorders characterized by nerve damage which comprise implanting stable, homogeneous post-mitotic human neurons at or near a site of said nerve damage are also disclosed.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: April 10, 2001
    Assignee: Trustees of the University of Pennsylvania
    Inventors: Virginia M. -Y. Lee, John Q. Trojanowski
  • Patent number: 6214986
    Abstract: Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: April 10, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Brett P. Monia, Brian J. Nickoloff, QingQing Zhang
  • Patent number: 6210892
    Abstract: The present invention provides compositions and methods for controlling the behavior of a cell, tissue or organism through antisense modulation of mRNA processing, using antisense compounds which does not support cleavage of the mRNA target.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: April 3, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Stanley T. Cooke, Muthiah Manoharan, Jacqueline R. Wyatt, Brenda F. Baker, Brett P. Monia, Susan M. Freier, Robert McKay, James G. Karras
  • Patent number: 6204055
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: March 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Eric G. Marcusson
  • Patent number: 6204028
    Abstract: A method of screening compounds for antiviral activity against a selected human herpesvirus by measuring inhibition of DNA synthesis by DNA polymerase and processivity factor of the selected human herpesvirus in the presence of the compound is provided.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: March 20, 2001
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert P. Ricciardi, Kai Lin
  • Patent number: 6200807
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SHP-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SHP-2. Methods of using these compounds for modulation of SHP-2 expression and for treatment of diseases associated with expression of SHP-2 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: March 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6197584
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: March 6, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6198017
    Abstract: Medicinal pressure-sensitive adhesives, adhering to both dry and wet skin, characterized by a mixture of a) 20-50 wt-% of a hydrophilic (meth)acrylate copolymerizate containing tertiary amino groups, b) 20-50 wt-% of a hydrophobic (meth)acrylate copolymerizate containing carboxyl groups, c) 10-40 wt-% of one or more mono- or dicarboxylic acids, d) 0-10 wt-% of a polyol, and e) 0.02-0.5 wt-% of a cross-linking system reacting with at least one copolymerizate, whereby the sum of components a to e equals 100 wt-%, with a water-vapor permeability of ≧30,000 g·m−2·24 h−1, measured on a pressure-sensitive adhesive film with a thickness of 40 &mgr;m.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: March 6, 2001
    Assignee: Lohmann GmbH & Co. KG
    Inventors: Arno Basedow, Frank Kura, Kurt Seeger
  • Patent number: 6190872
    Abstract: A method of identifying and monitoring patients at risk for developing a systemic inflammatory condition prior to development of signs and symptoms using a systemic mediator-associated physiologic test profile is provided.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: February 20, 2001
    Inventor: Gus J. Slotman
  • Patent number: 6190869
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein kinase C-theta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein kinase C-theta. Methods of using these compounds for modulation of Protein kinase C-theta expression and for treatment of diseases associated with expression of Protein kinase C-theta are provided.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: February 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6187787
    Abstract: A series of bis-acridinyl DNA intercalating agents with anticancer cell activity represented by formula (I), where Z is a linear arrangement of multiple aromatic rings, containing at least three aromatic rings, or at least two alicyclic rings, said rings being linked in a 1,4 or 1,3 manner are provided. Methods of inhibiting cancer cells and treating patients having cancer with these agents are also provided.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: February 13, 2001
    Assignee: Trustees of Dartmouth College
    Inventors: Gordon W. Gribble, Gary D. Jaycox, Michael Mosher
  • Patent number: 6187542
    Abstract: A method of predicting the clinical outcome of patients suffering from congestive heart failure by identifying patients with a mutant allele of the AMPD1 gene is provided. Methods for increasing survival time in patients suffering from congestive heart failure by administering compositions which inhibit AMPD1 activity are also provided.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: February 13, 2001
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Edward Holmes, Evan Loh, Judith Swain
  • Patent number: 6187545
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Jacqueline Wyatt, Lex M. Cowsert
  • Patent number: 6187586
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-3. Methods of using these compounds for modulation of Akt-3 expression and for treatment of diseases associated with expression of Akt-3 are provided.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Richard A. Roth
  • Patent number: 6187587
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Vickie L. Brown-Driver, Lex M. Cowsert